JAK1 and myelofibrosis: Ruxolitinib is a potent JAK1 and JAK2 inhibitor, with good safety profile, that is approved for myelofibrosis [12, 13] and polycythemia vera [14], two myeloproliferative neoplasms characterized by over-inflammation.